OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:24 UTC. Every row links to its source record.

CDKN2A cyclin dependent kinase inhibitor 2A

ENSG00000147889 · protein coding · Open Targets profile

Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Plays a role in inhibiting ribosome biogenesis, perhaps by binding to the nucleolar localization sequence of transcription termination factor TTF1, and thereby preventing nucleolar localization of TTF1 (By similarity). Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. {ECO:0000250|UniProtKB:Q64364, ECO:0000269|PubMed:11314011, ECO:0000269|PubMed:11314038, ECO:0000269|PubMed:12660818, ECO:0000269|PubMed:14636574, ECO:0000269|PubMed:15361825, ECO:0000269|PubMed:15567177, ECO:0000269|PubMed:15876874, ECO:0000269|PubMed:15989956, ECO:0000269|PubMed:16713577, ECO:0000269|PubMed:18305112, ECO:0000269|PubMed:22094112, ECO:0000269|PubMed:9724636}.

In 9 of 15 cancers, the evidence for CDKN2A comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751dysplastic nevusdysplastic nevusdysplastic nevus: somatic 0.46dysplastic nevus: germline 0.97familial atypical multiple mole melanom…familial atypical multiple mole melanoma syndromefamilial atypical multiple mole melanoma syndrome: germline 0.85melanomamelanomamelanoma: somatic 0.80melanoma: germline 0.86cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61cutaneous melanoma: germline 0.82melanoma and neural system tumor syndro…melanoma and neural system tumor syndromemelanoma and neural system tumor syndrome: germline 0.93familial melanomafamilial melanomafamilial melanoma: germline 0.95squamous cell lung carcinomasquamous cell lung carcinomasquamous cell lung carcinoma: somatic 0.77squamous cell lung carcinoma: germline 0.08head and neck squamous cell carcinomahead and neck squamous cell carcinomahead and neck squamous cell carcinoma: somatic 0.82hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.77hepatocellular carcinoma: germline 0.14esophageal canceresophageal canceresophageal cancer: somatic 0.91esophageal cancer: germline 0.14superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61superficial spreading melanoma: germline 0.80hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95pancreatic adenocarcinomapancreatic adenocarcinomapancreatic adenocarcinoma: somatic 0.92urinary bladder cancerurinary bladder cancerurinary bladder cancer: somatic 0.71urinary bladder cancer: germline 0.05plasma cell myelomaplasma cell myelomaplasma cell myeloma: somatic 0.46plasma cell myeloma: germline 0.78

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 0.26919999718666077 (upper bound 0.6957700252532959). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of CDKN2A's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of CDKN2A's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.